Angiotensin-converting enzyme inhibition in the prevention and treatment of chronic renal damage in the hypertensive fawn-hooded rat

• Published in: Journal of the American Society of Nephrology Vol. 8; no. 2; pp. 249 - 259
• Main Authors: VERSEPUT, G. H, PROVOOST, A. P, BRAAM, B. B, WEENING, J. J, KOOMANS, H. A
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 01.02.1997
• Subjects: Age Factors; Albuminuria - drug therapy; Albuminuria - etiology; Albuminuria - prevention & control; Angiotensin-Converting Enzyme Inhibitors - administration & dosage; Angiotensin-Converting Enzyme Inhibitors - pharmacology; Animals; Biological and medical sciences; Blood Pressure - drug effects; Glomerulonephritis; Glomerulosclerosis, Focal Segmental - drug therapy; Glomerulosclerosis, Focal Segmental - etiology; Glomerulosclerosis, Focal Segmental - prevention & control; Hypertension - complications; Hypertension - drug therapy; Hypertension - physiopathology; Kidney Failure, Chronic - drug therapy; Kidney Failure, Chronic - etiology; Kidney Failure, Chronic - prevention & control; Male; Medical sciences; Nephrology. Urinary tract diseases; Nephropathies. Renovascular diseases. Renal failure; Rats; Kidney disease; Hypertension; Animal model; Urinary system disease; Rat; Treatment efficiency; Rodentia; Cardiovascular disease; Prevention; Focal glomerulonephritis; Vertebrata; Chronic; Mammalia; Animal; Complication; ACE inhibitor
• ISSN: 1046-6673; 1533-3450
• DOI: 10.1681/ASN.V82249

The spontaneously hypertensive fawn-hooded rat (FHH) develops accelerated albuminuria and focal glomerular sclerosis (FGS), leading to ESRD and shortening of lifespan. The FHH is characterized by moderate systemic hypertension, a relatively low afferent to efferent arteriolar resistance ratio, and glomerular hypertension. The FHH study presented here was designed to examine the efficacy of early-onset, late-onset, or early-temporary angiotensin I-converting enzyme inhibition (ACE-i) in ameliorating long-term hypertension and FGS, and improving survival, as well as to relate its protective efficacy to preexistent FGS and to reduction of glomerular pressure (PGC) Untreated rats developed hypertension and high PGC, and all (N = 22) except one died of ESRD within the 72-wk follow-up period. Early-onset (at 7 wk of age) ACE-i prevented development of systemic and glomerular hypertension, and it largely prevented proteinuria and FGS; all rats survived throughout the follow-up period. Rats treated with late-onset (22 wk) ACE-i were hypertensive and proteinuric at the start of ACE-i, and they showed beginning FGS. ACE-i corrected the hypertension, albuminuria, and PGC but could not fully prevent some hypertension, albuminuria, and FGS at the later stage. Early-temporary (7 to 22 wk) ACE-i adequately controlled blood pressure and development of FGS during therapy, but after withdrawal of ACE-i, systemic and glomerular hypertension developed as in untreated animals. This regimen postponed but did not control FGS development and early mortality. The results of this study indicate that: (1) early-onset ACE-i very effectively protects against development of renal damage in the FHH; (2) this protection is associated with normalization of the elevated glomerular capillary pressure; (3) ACE-i cannot completely prevent further development of previously established FGS, despite lowering glomerular capillary pressure; (4) early-temporary ACE-i has no long-term controlling effect on arterial and glomerular pressure, and it cannot control development of FGS.